Edition:
United Kingdom

People: Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

116.53USD
18 Jun 2019
Change (% chg)

$2.54 (+2.23%)
Prev Close
$113.99
Open
$115.00
Day's High
$118.34
Day's Low
$113.07
Volume
185,450
Avg. Vol
103,316
52-wk High
$194.56
52-wk Low
$105.19

Hedrick, Eric 

Dr. Eric E. Hedrick, M.D. is Interim Chief Medical Officer, Immuno-Oncology of the Company. He has served in different roles at the Company since June 2015 and currently holds the position of Chief Advisor. He was previously Chief Medical Officer at Epizyme, Vice President of Oncology Development and Interim Chief Medical Officer at Pharmacyclics, and Group Medical Director at Genentech. Prior to joining the industry, Dr. Hedrick was an Attending Physician on the Hematology Service at Memorial Sloan-Kettering Cancer Center. He has an M.D. from the University of Maryland School of Medicine.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --